1. Biochemical Efficacy and Safety of a New, Ready-to-Use, Liquid Alpha-1-Proteinase Inhibitor, GLASSIA (Alpha1-Proteinase Inhibitor (Human), Intravenous). (1st February 2014) Authors: Sandhaus, Robert A.; Stocks, James; Rouhani, Farshid N.; Brantly, Mark; Strauss, Pnina Journal: COPD Issue: Volume 11:Number 1(2014:Feb.) Page Start: 17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Biochemical Efficacy and Safety of a New, Ready-to-Use, Liquid Alpha-1-Proteinase Inhibitor, GLASSIA (Alpha1-Proteinase Inhibitor (Human), Intravenous). (1st February 2014) Authors: Sandhaus, Robert A.; Stocks, James; Rouhani, Farshid N.; Brantly, Mark; Strauss, Pnina Journal: COPD Issue: Volume 11:Number 1(2014:Feb.) Page Start: 17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Quantitative disease progression model of α‐1 proteinase inhibitor therapy on computed tomography lung density in patients with α‐1 antitrypsin deficiency. (11th August 2017) Authors: Tortorici, Michael A.; Rogers, James A.; Vit, Oliver; Bexon, Martin; Sandhaus, Robert A.; Burdon, Jonathan; Chorostowska‐Wynimko, Joanna; Thompson, Philip; Stocks, James; McElvaney, Noel G.; Chapman, Kenneth R.; Edelman, Jonathan M. Journal: British journal of clinical pharmacology Issue: Volume 83:Number 11(2017) Page Start: 2386 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗